LL-37 vs MOTS-c
Side-by-side comparison of key properties, dosing, and research.
- Summary
- LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Half-Life
- Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
- Estimated 1–2 hours
- Admin Route
- SubQ, Topical, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- 5–15 mg
- Frequency
- 2–3x per week
- 3–5 times per week
- Key Benefits
- Broad-spectrum antimicrobial (bacteria, fungi, viruses)
- Promotes wound healing and angiogenesis
- Immune system modulation — enhances innate immunity
- Reduces LPS-mediated endotoxemia
- Anti-biofilm activity against resistant organisms
- Promotes tissue regeneration and keratinocyte migration
- May protect against sepsis
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Side Effects
- Injection site redness and irritation
- Mild inflammatory response at injection site
- Potential pro-inflammatory at high doses
- Rare: fever or flu-like symptoms at initiation
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Stacks With
- —
- —